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SUMMARY – Bone endures a lifelong course of construction and destruction, with bone marker 
(BM) molecules released during this cycle. The field of measuring BM levels in synovial fluid and 
peripheral blood is a cardinal part of bone research within modern clinical medicine and has devel-
oped extensively in the last years. The purpose of our work was to convey an up-to-date overview on 
synovial fluid and serum BMs in the most common arthropathies.
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Introduction
In adults, bone is an active organ that undergoes a 
constant remodeling process of formation and resorp-
tion. Therefore, these two reverse activities can be mea-
sured with the help of specific bone markers (BMs). 
Since information on bone remodeling cycle could 
represent an early indicator of pathologic changes in 
bones, measuring BM levels can provide important 
data on therapeutic response, faster than measuring 
bone mass.
Arthropathies describe a large domain of joint dis-
eases, which can be classified depending on etiologic 
factors. The prevalence of inflammatory joint diseases 
has been rising continuously and environmental fac-
tors seem to play an important role. The main symp-
toms of arthritis (pain, redness, and swelling of the 
joints) often limit the ability to perform everyday ac-
tivities, being the leading cause of disability.
Lately, more attention has been paid to studying 
diagnostic methods of arthropathies. On the one hand, 
several studies on osteoarthritis (OA), rheumatoid ar-
thritis (RA) and osteoporosis have been published 
with the purpose of helping the clinician make an 
early diagnosis and achieve better treatment results. 
On the other hand, some conditions are still over-
looked and undertreated. This phenomenon has been 
observed in the calcium pyrophosphate deposition 
(CPPD) disease, where clinicians meet difficulties in 
diagnosing and treating the condition.
The aim of this review was to grant an overview of 
up-to-date knowledge collected over the past 15 years 
regarding synovial fluid (SF) and serum BMs in the 
most common arthropathies. Attention was focused 
on osteocalcin (OC), beta-crosslaps, osteoprotegerin 
(OPG) and matrix Gla protein (MGP) levels in OA, 
crystal arthropathies, RA, osteoporosis and inflamma-
tory joint disease, also including relevant genetic 
markers.
Bone Markers
As it is well known, there are two different types of 
BMs: formation BMs (e.g., procollagen type I exten-
sion peptides, bone-specific alkaline phosphatase and 
OC) and resorption BMs (e.g., tartrate-resistant acid 
phosphatase, collagen cross-link molecules, cross-
linked telopeptides of collagen I, hydroxyproline, hy-
droxylysine-glycoside, OPG and bone sialoprotein).
Beta-crosslaps
Bone matrix is produced by osteoblasts and con-
tains predominantly type 1 collagen. During bone re-
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sorption, collagen breakdown leads to N and C-telo-
peptides1. Two fragments result from the C-telopep-
tide end: ICTP (cross-linked carboxyterminal telo-
peptide of type I collagen) and CTX (C-terminal 
cross-linked telopeptide of type I collagen). Both frag-
ments are used as clinical markers and can be mea-
sured in serum, SF or urine by specific immunoassays. 
ICTP and CTX undergo different degradation path-
ways, therefore these two markers help in distinguish-
ing different bone pathologies2. Serum beta telopep-
tide immunoassays have also been used to evaluate 
bone destruction in various diseases, e.g., cancer3-5, 
endocrine pathologies6-8, or in hemodialysis patients9,10.
Matrix Gla protein
Matrix Gla protein is an extracellular matrix pro-
tein, member of the mineral-binding Gla protein fam-
ily, found in humans in cartilage, bone, vascular smooth 
muscle cells, but also in animals11. It acts as an inhibi-
tor of ectopic tissue calcification.
Recently, Marulanda et al.12 demonstrated in a 
mouse model that MGP deficiency causes septal 
chondrocyte apoptosis, thus involving MGP in nasal 
septum development. Since there are phenotypic simi-
larities between mice and humans, the absence of 
MGP in mice can be a solid base for understanding 
and treating craniofacial anomalies.
The polymorphism of MGP gene screening was 
published in 2000 by Herrmann et al.13, but the focus 
of research was on studying the association between 
MGP rs4236 and rs1800801 genetic variants and arte-
rial wall calcification14. The gene codes a vitamin-K 
dependent protein that regulates the amount of carti-
lage mineralization by regulating chondrocyte matura-
tion and bone formation15. Also, Nakatani et al.16 dem-
onstrated that MGP could lead to bone demineraliza-
tion due to high levels of magnesium in plasma.
The activity of MGP as a calcification inhibitor 
 requires two post-translational modifications, i.e. 
γ-glutamate carboxylation and serine phosphorylation. 
MGP contains 9 glutamate residues, 5 of them being 
γ-carboxylated by vitamin K-dependent γ-glutamate 
carboxylase, thus contributing to calcium binding and 
crystal growth control17.
Studies have shown that serine phosphorylation 
has also an important role in MGP functionality18. 
Both post-translational modifications lead to different 
types of MGP species, i.e. phosphorylated (pMGP), 
dephosphorylated (dpMGP), carboxylated (cMGP), 
uncarboxylated (ucMGP), or different combinations 
of these. Unfortunately, not all the conformations can 
be measured, but their circulating levels may reflect the 
degree of calcification in the vascular wall19.
Radioimmunoassay and enzyme-linked immuno-
sorbent assays have been used to assess circulating 
MGP in order to establish its prognostic value in car-
diovascular diseases and patients with end-stage renal 
disease20. Cranenburg et al.19 compared two mono-
antibody and two dual-antibody MGP assays in sev-
eral pathologies. Although the dual-antibody assay 
measuring dephosphorylated-uncarboxylated MGP 
(dp-ucMGP) was appropriate to evaluate vascular vi-
tamin K status, dp-ucMGP levels were also elevated in 
patients with gout, some individuals with RA and sys-
temic lupus erythematosus.
Matrix Gla protein was studied in a wide range of 
diseases from tumoral pathologies21, including breast 
cancer22, renal diseases23 and arterial calcification24. In 
the last years, utilization of MGP as a BM has attract-
ed much attention from researchers, as discussed be-
low.
Osteocalcin
Another vitamin K-dependent protein, OC, is syn-
thesized by osteoblasts and has an important role in 
bone formation. Gamma-glutamyl carboxylase and 
vitamin K (acting as a coenzyme) convert uncarboxyl-
ated OC into carboxylated OC. However, in humans, 
the carboxylation process is not fully completed, as the 
uncarboxylated OC is to be found in bone and serum. 
The majority of OC is deposited in bone matrix, where 
the main function is not only to bind calcium and help 
bone formation, but also to regulate bone cell activity. 
It was demonstrated that a small proportion of OC 
(20%) reaches the bloodstream and is rapidly cleared 
in a population with preserved kidney function25.
Osteoprotegerin
Osteoprotegerin, also known as osteoclastogenesis 
inhibitory factor, is an affiliate of the tumor necrosis 
factor (TNF) receptor superfamily member 11B, act-
ing in human body as a cytokine of the TNF receptor 
superfamily26. The TNF/TNF receptor superfamily is 
composed of more than 40 members. Their main role 
was proven not only to control genes for different cel-
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lular processes (differentiation, survival and apoptosis), 
but also to coordinate numerous organ functions27.
Osteoprotegerin follows a very complex bone re-
modeling pathway, which implies another member of 
TNF superfamily, the receptor activator of nuclear 
factor-κβ (RANK) and its ligand (RANKL). RANK 
and RANKL binding leads to transformation of pro-
osteoclast into mature osteoclasts, causing bone resorp-
tion. OPG controls osteoclastogenesis via competing 
with RANK and inhibiting the RANKL-RANK in-
teraction. As a result, it prevents bone destruction. 
Furthermore, OPG has the ability to interact with 
TNF-related apoptosis-inducing ligand (TRAIL), 
another TNF family member, with the consequence of 
inducing apoptosis in numerous cancer cells28.
Osteoprotegerin expression was found in a consid-
erable variety of tissues in the human body, either up- 
or down-regulating them, e.g., osteoblasts, endothelial 
cells, smooth muscle cells, dendritic cells29. In addition, 
several studies highlighted the OPG function in the 
pathogenesis of atherosclerosis30, diabetes mellitus and 
renal dysfunction31.
Arthropathies
The term arthropathy includes any disease affecting 
the joint. Depending on the etiologic factor, there are 
multiple classifications of joint diseases in the litera-
ture. Lambert32 simplifies them into four categories, as 
follows: degenerative or OA, inflammatory, autoim-
mune, and septic arthritis. Articular cartilage primarily 
contains type II collagen, proteoglycans, chondrocytes 
and water. A constant equilibrium among these com-
ponents is needed to maintain a healthy articular car-
tilage. Regardless of the cause that disrupts the equi-
librium, joint diseases may cause swelling, pain, stiff-
ness, and could lead not only to overall mobility reduc-
tion, but also compromise the quality of life33. 
Hereunder, several bone and cartilage pathologies are 
briefly reviewed.
Osteoarthritis
Osteoarthritis is considered the most common 
chronic join disease that affects around 10% of men 
and 18% of women aged over 60 years34. The etiology 
of OA is different when referring to primary and sec-
ondary OA. For several years, great efforts have been 
invested in the study of risk factors. Besides age and 
sex, which seem to be the major ones, there are others 
to be mentioned, i.e. genetics, bone metabolism, obe-
sity, diet, ethnicity and joint-level risk factors. Despite 
all efforts, the prevalence of OA has been continuously 
rising35. The main characteristic of OA is the loss of 
articular cartilage and subchondral bone sclerosis, 
which leads to activity-related pain, morning joint 
stiffness, and finally loss of joint function36. The focus 
of recent research was on early identification of the 
pathology. In this respect, Mobasheri and Henrotin37 
studied OA biomarkers to diagnose, predict or assess 
the patient physical condition.
Osteoarthritis may not only occur as a primary 
form, but also as secondary form, depending on the 
identifiable cause. The most interesting approach to 
this issue has been proposed by Yamaguchi et al.38 in a 
research of hip OA due to osteonecrosis of the femoral 
head, rapidly destructive arthrosis and developmental 
dysplasia of the hip. In that study, bone and cartilage 
marker levels in SF were analyzed and compared. The 
overall measurement results showed a bone formative 
condition in patients with osteonecrosis of the femoral 
head and elevated osteoclastic activity in patients with 
rapidly destructive arthrosis, thus adding a new intro-
spective into the pathophysiology and clinical evolu-
tion of each disease38.
Inflammatory and autoimmune arthritis
The most common type of autoimmune arthritis is 
RA. On the one hand, the pathology describes inflam-
mation of the synovial membrane causing joint swell-
ing, but on the other hand, RA can lead to extra-artic-
ular pathologies. The most commonly affected joints 
are small and medium joints. A typical patient has 
symmetrical inflammation in the wrist and metacar-
pophalangeal joints. Genetic factor was found to ac-
count for 50% risk of developing RA39. In their study, 
Gland et al.40 investigated the role of epigenetics and 
considered both genetics and epigenetics to contribute 
slightly to RA development.
Another important autoimmune arthritis is psori-
atic arthritis (PS). In terms of differentiation between 
RA and PS, Verheul et al.41 concluded on the occur-
rence of autoantibodies in RA and their absence in PS 
to be the key, but various markers should be longitudi-
nally assessed in future studies.
Juvenile idiopathic arthritis ( JIA), previously 
known as juvenile rheumatoid arthritis is one of the 
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most common disorders found in children and adoles-
cents. The pathology is difficult to diagnose due to the 
lack of pediatric symptoms. There is no reliable and 
specific blood test to establish the diagnosis, and treat-
ment may consist of intra-articular steroid injections. 
Carrasco et al.42 investigated changes in bone forma-
tion and resorption markers from 198 corticosteroid-
free children with JIA with daily oral calcium supple-
mentation. They found that serum OC level, among 
other hormones and minerals, was significantly lower 
in the calcium supplementation group.
Crystal arthropathies
Crystal arthropathies are skeletal diseases caused 
by deposition of mineral compounds mainly in joints 
but also in periarticular tissues43. Gout and chondro-
calcinosis (also known as pseudogout, commonly 
caused by CPPD) are the most frequently seen forms 
of crystal arthropathies. Crystal composition, shape 
and birefringence detected by polarized light micros-
copy, first suggested by McCarty et al.44 in 1962, is now 
the gold standard in establishing the diagnosis45. Gout 
presents negative birefringence needle-like monoso-
dium urate crystals, whereas weakly positive, rhom-
boid calcium pyrophosphate crystals are typical for 
chondrocalcinosis. Moreover, McQueen et al.46 stud-
ied the importance of imaging diagnosis in crystal ar-
thropathies. Thereby, ultrasonography, radiography, 
computed tomography, dual energy computer tomog-
raphy and magnetic resonance imaging could be useful 
tools to identify crystal depositions in joints.
The presence of crystals in joint cavity results in 
synovitis and pain. Although gout is linked to hyper-
uricemia and the pathologic mechanism of pseudog-
out remains mainly unknown, there is evidence in lit-
erature that gout and chondrocalcinosis may coexist. 
The association of gout and chondrocalcinosis in the 
same joint was found in 199847. Ten years later, an-
other coexistence case of gout and chondrocalcinosis 
in the same joints and in both hands was described48. 
Clinical recognition and differentiation of gout and 
CPPD from other arthropathies may be the key to an 
accurate treatment. Acute gout and CPPD symptoms 
may be controlled with similar drugs such as colchi-
cine, nonsteroidal anti-inflammatory drugs and corti-
costeroids. It is known that the use of urate lowering 
therapy has a substantial effect on controlling chronic 
gout. On the contrary, approaching chronic CPPD 
may be problematic to clinician due to the high rate of 
comorbidities49. No significant effect of methotrexate 
was found in chronic CPPD, thus the patient should 
be referred to a rheumatologist when choosing thera-
py50. On the other hand, researchers highlighted the 
anti-inflammatory effect of nanoparticles in treating 
chronic crystal-induced arthropathies, and by virtue of 
beneficial effects, they should be considered an effi-
cient therapy option51.
Bone Markers in Arthropathies  
and Osteoporosis
Bone and joint destruction in rheumatic diseases 
can be quantified by analyzing BM levels in serum 
and/or SF. As any biological marker, measuring BMs 
may present some limitations such as pre-analytical, 
analytical and post-analytical variability, especially 
when measuring resorption markers. According to 
Hlaing et al.52, there are some steps that clinicians 
could follow in order to reduce BM variability and im-
prove clinical outcomes. Despite their variability, many 
BMs are used in clinical practice to diagnose or moni-
tor endocrine, oncologic, renal and rheumatic disor-
ders that have influence on bone diseases53.
Recently, ever more attention has been paid to BM 
measurements in SF. Synovial fluid is a viscous, pro-
tein-rich fluid produced by the synovial membrane. 
Besides reducing friction between opposing surfaces of 
cartilage and shock absorption, SF is a medium for 
breakdown products secreted in joint diseases, which 
may be first detected in SF before serum. Several 
methods could be helpful in diagnosing arthropathies. 
In a recent paper by Dubey et al.54, the presence of re-
active arthritis metabolites in SF was investigated with 
nuclear magnetic resonance spectroscopy in order 
to bring a better clinical perspective. Furthermore, 
a study of genetic markers from 2010 showed that 
SF microRNAs may represent valuable biomarkers for 
RA and OA55.
However, there still is a significant potential for 
improvements in identifying reliable BMs. As an ex-
ample, combined measuring of ucMGP in serum and 
SF may be considered a useful joint inflammatory 
marker in patients with arthritis56. For understanding 
frequent pathologies such as OA, RA, PS or JIA, pro-
teomics in SF based on mass spectrometry techniques 
is becoming more popular in BMs validation57. Early 
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diagnosis of joint diseases using SF biomarkers has be-
come a strong future perspective that will help physi-
cians achieve better treatment for patients58.
Osteoarthritis: a long studied disease
The incidence of knee OA is likely to increase due 
to aging and the increasing rate of overweight and 
obesity in general population. Previous studies sug-
gested that low vitamin K status was associated with 
higher OA prevalence and incidence59. It is already 
well established that OA is characterized by changes 
in bone cells along with mineralization of the matrix. 
Articular chondrocytes in OA undergo hypertrophy60, 
with vitamin K being essential to prevent soft tissue 
mineralization, thus a low circulating level of MGP 
leads to development of cartilage calcification61.
Related to MGP, fetuin is also a calcium binding 
protein and an inhibitor of calcium phosphate salt for-
mation, synthesized by the liver and secreted into the 
bloodstream. In bone, fetuin interacts with cMGP, 
forming a complex via calcium phosphate that is re-
leased into the bloodstream as a fetuin-MGP com-
plex62. In 2010, a study among OA patients63 showed 
an important difference in MGP production between 
normal chondrocytes and chondrocytes isolated from 
OA cartilage; normal cells synthesized functional 
cMGP, whereas OA cells produced primarily ucMGP. 
Wallin et al.63 demonstrated not only that cartilage 
contained fetuin, but also that fetuin uptake by chon-
drocytes in cell culture had a similar mechanism with 
fetuin uptake by cultured vascular smooth muscle cells. 
Moreover, they revealed the fetuin-MGP complex to 
be present in normal chondrocyte vesicles but not in 
the vesicles from OA chondrocytes. From the out-
comes of this study, it is possible to conclude that the 
absence of cMGP and cMG-fetuin complex in OA 
cells and vesicles could explain increased mineraliza-
tion of osteoarthritic cartilage.
The possible association between circulating vita-
min K, dp-ucMGP (the inactive conformation of 
MGP, related to vitamin K deficiency) and structural 
features of the knee (as assessed by magnetic resonance 
imaging) were evaluated by Shea et al.64 using a cross-
sectional and longitudinal approach. They carried out a 
study to find if lower plasma vitamin K and higher 
dp-ucMGP could be associated with a higher preva-
lence and progression of knee OA. They found a posi-
tive association between plasma dp-ucMGP and the 
presence of knee OA features, but there was no clear 
evidence for association between dp-ucMGP and OA 
progression64.
An intriguing approach was proposed in 2015 by 
Park et al.65, who showed that a fluoro-microbeads 
guiding chip may be a new method of detecting the 
CTX-II BM in serum and urine to establish the diag-
nosis of OA. Another study from 2016 on rabbits with 
knee OA66 demonstrated the efficiency of short thrust 
needling (close-to-bone needling) plus electroacu-
puncture in healing pathologic knee cartilage tissue by 
regulating cartilage vitamin K dependent gamma-glu-
tamyl carboxylase expression, which resulted in lower 
levels of serum ucMGP. Instead, in humans, ucMGP 
levels measured in SF might serve as a biomarker for 
assessing knee OA progression67. Serum OPG (among 
other bone turnover markers) has also been referred to 
as a valuable biologic marker in predicting knee OA 
radiographic severity68.
Chondrocalcinosis and bone markers
Chondrocalcinosis is a rheumatic disease that leads 
to acute and chronic arthritis due to accumulation of 
calcium pyrophosphate dihydrate crystals in joints. In 
the last years, the EULAR CPPD Task Force has sug-
gested CPPD as the umbrella term for all instances of 
calcium pyrophosphate (CPP) crystal deposition 
which includes asymptomatic CPPD, OA with 
CPPD, acute CPP crystal arthritis (replacing the term 
pseudogout) and chronic CPP crystal inflammatory 
arthritis. Chondrocalcinosis or cartilage calcification 
(CC) is only used for imaging or histologic examina-
tion and may occur not only in CPPD, but also in 
other joint pathologies. Similar to gout, CPPD associ-
ates various clinical presentations such as asymptom-
atic CPPD, OA with CPPD, acute and chronic CPP 
crystal arthritis69.
Calcium pyrophosphate crystals deposited in joints 
require inorganic pyrophosphate (PPi) and calcium. 
All the PPi found in the body is synthesized exclu-
sively through endogenous pathway. Chondrocytes 
produce PPi, which uses ankylosis transporter (ANKH 
in humans and ANK transporter in mice) to pass the 
cell membrane. ANKH gene is located on the short 
(p) arm of chromosome 5 and loss of its function re-
sulted in low PPi, whereas overexpression of the gene 
generated high levels of PPi and subsequent CPPD70. 
Using immunohistochemistry and in situ hybridiza-
Roxana Răduț et al. Bone markers in arthropathies
Acta Clin Croat, Vol. 58, No. 4, 2019 721
tion techniques, Uzuki et al.71 showed the number of 
ANKH-positive cells in joint tissues from patients 
with CPPD to be higher than in OA patients without 
crystal deposition or controls.
Although CPPD has been reported as sporadic 
and primarily affecting the elderly, younger individuals 
with familial CPPD have also been described in the 
literature70. Interest in the field of genetics appears to 
increase as more studies of ANKH protein in familial 
CPPD diseases have been published in the last years. 
It was established that mutation in CCAL 2 locus on 
chromosome 5 was linked to an autosomal-dominant 
form of CPPD, but mutation on chromosome 8 
(CCAL 1) was also related to CPPD72,73. A subse-
quent study revealed that mutation in TNFRSF11B 
gene encoding OPG might lead to an association of 
OA and chondrocalcinosis74; in the study conducted 
by William et al.75 in 2018, CCAL1 locus on chromo-
some 8 was identified as TNFRSF11B (OPG) gene.
Calcium pyrophosphate crystals induce synovial 
inflammation and other effects on joint tissues on the 
account of stimulation of prostaglandin E and matrix 
metalloproteinase production. All these changes in the 
cartilage will eventually lead to cartilage degenera-
tion76.
The gold standard in CPPD diagnosis is micro-
scopic analysis of SF by visualizing the positive bire-
fringence rhomboid-shaped crystals. An early diagno-
sis of microcrystalline arthritis can usually be per-
formed by using noninvasive methods. The importance 
of ultrasonography in the differential diagnosis of 
early arthritis has been highlighted recently in a case 
report of a male suffering from Gitelman syndrome, in 
which cartilage calcification could be considered an 
early marker77, but additional studies are still required.
It is already known that CPPD is an underdiag-
nosed and undertreated condition. However, studies 
on using BMs from SF for diagnostic purposes are still 
lacking. An example of measuring molecular frag-
ments in SF is presented by Lohmander et al.78 in pa-
tients with OA and other types of knee arthritis, 
among which pseudogout was mentioned. Strong evi-
dence for high levels of cross-linked C-telopeptide 
fragments of type II collagen (CTX-II) being released 
soon after joint injury or arthritis had been proved. 
Therefore, CTX-II levels may be an important step 
that should be considered in diagnostic and treatment 
protocol.
Rheumatoid arthritis
Patients with RA have a higher risk of developing 
secondary osteoporosis. From this perspective, Ma-
tuszewska and Szechiński79 assessed specific BM levels 
in RA patients undergoing therapy for osteogene-
sis and proved that reduced levels of OC might indi-
cate a lower rate of osteogenesis. In RA patients, sev-
eral serum and synovial BMs have been used for prog-
nosis and clinical diagnosis. Although the results were 
promising, more research in BMs validation is neces-
sary before obtaining a definitive answer for prediction 
of therapeutic response. As reported by Marotte et 
al.80, CTX-II levels might be useful to monitor treat-
ment and evaluation of RA.
Osteoporosis
Osteoporosis was defined as deterioration of bone 
mass and is associated with increased risk of fracture, 
bone fractures being manifest in females over 65 years 
of age and to a lesser extent in males over 6581. Osteo-
porotic fractures pose a major problem worldwide; 
therefore, the Bone Marker Standards Working 
Group82 proposes the specific markers of bone resorp-
tion and bone formation be taken into consideration 
in all future studies. Since CTX is a BM which pres-
ents an advantage of having low biologic variability 
when collected in EDTA-containing tubes, it is con-
sidered to be the bone resorption marker of choice83.
Among other BMs, lower levels of OC and CTX 
were found in overweight postmenopausal women 
with diabetes type 284, and higher MGP levels in post-
menopausal women with calcified minor carotid ste-
nosis, regardless of the presence of osteopenia and os-
teoporosis85.
Moreover, in 2016, it was shown that BMs may 
currently be used not only in the assessment of fracture 
risk but also in monitoring osteoporotic treatment86.
Recently, considerable attention has been paid to 
BM polymorphisms in osteoporosis. A study on femo-
ral neck bone in men demonstrated the loss of bone 
mineral density to be associated with MGP -7G>A 
and MGP Thr83Ala polymorphisms87. Therefore, the 
authors suggest that some MGP variants may influ-
ence the expression of MGP gene and the progression 
of bone loss could be predicted at an earlier stage. An-
other interesting approach to this issue has been pro-
posed by Ling et al.88 in a study among Chinese popu-
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lation, suggesting that rs1800247 polymorphism in 
OC gene may influence serum total OC levels and the 
risk of osteoporosis.
Conclusions
Bone and joint destruction can be quantified by 
analyzing BM levels in serum and SF. Studies have 
shown that breakdown products may first be detected 
in SF before serum, therefore analyzing SF should be 
further considered.
Bone markers are a useful accessory for the diagno-
sis and therapeutic monitoring of bone metabolic dis-
orders, but their use has to be tempered by known 
limitations in clinical utility and by preanalytical vari-
ables that complicate the interpretation. BMs could 
complete the results of imaging techniques, thus con-
tributing to faster and accurate diagnosis. With devel-
opment of new techniques and new markers, the fu-
ture of arthropathy management sounds promising.
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Sažetak
KOŠTANI BILJEZI U ARTROPATIJAMA
R. Răduț, A. M. Crăciun i C. N. Silaghi
Kost podliježe stalnoj izgradnji i razgradnji tijekom čitavog života. Tijekom tog procesa oslobađaju se molekule koštanih 
biljega. Područje mjerenja razina koštanih biljega u sinovijskoj tekućini i perifernoj krvi bitan su dio istraživanja kosti u su-
vremenoj kliničkoj medicini i uvelike se razvija posljednjih godina. Namjera ovoga rada je dati najnoviji pregled u području 
sinovijske tekućine i koštanih biljega u serumu kod najčešćih artropatija.
Ključne riječi: Sinovijska tekućina; Kosti; Zglob, bolesti
